© 2020 MJH Life Sciences and HCPLive. All rights reserved.
February 29, 2020
The RareWear program is designed to bridge medical device companies to rare disease patient applicants, seeking better disease and treatment monitoring.
New research suggests proposals aimed at reducing out of pocket costs may harm minimally-funded drug developers.
January 22, 2019
An Investigational New Drug application was approved to clinically assess AMT-130 as the first potential drug marketed for the neurodegenerative disease.
July 10, 2018
An isotopic-reinforced polyunsaturated fatty acids shows a reduction in cognitive deficits in a preclinical in vivo model of Huntington disease.
October 15, 2013
Results from the first multi-center interventional trial in premanifest HD research show that the antioxidant Coenzyme Q10 is associated with only mild or moderate side effects, even at higher doses.